CVS Is Unwinding the Deal That Built It
CVS will separate its roughly 9,000 drugstores from Aetna and Caremark by mid-2028, unwinding the vertical integration the 2018 Aetna merger created. Shares fell 12% anyway, despite a quarterly beat and raised guidance.
On Nov. 4, CVS Health announced its intent to split into two independent, publicly traded companies, with completion expected in the first half of 2028 and a structure intended to be tax-free to CVS Health and its shareholders. One company keeps Aetna, CVS Caremark and the specialty and primary care assets. The other takes roughly 9,000 drugstores, the mail pharmacy, MinuteClinic and the Health100 technology services business.
CVS reported third-quarter revenue of $108.4 billion, up 5.4% year over year, adjusted earnings of $2.09 a share against $1.60 a year earlier, and raised full-year guidance: adjusted earnings of at least $8.20, up from $7.90 to $8.10, operating cash flow of at least $15.5 billion, up from at least $11.5 billion. Shares fell about 12% anyway. Elevance Health rose 4% and Cigna climbed 3% the same day.
The decision unwinds the logic that built the modern company. CVS completed its roughly $69 billion acquisition of Aetna in November 2018, joining insurer, pharmacy benefit manager and drugstore chain in one company on the argument that owning every step from premium to prescription would help coordinate care and give it a competitive advantage. Eight years later, CVS is taking that structure apart by choice.
Two companies, one shareholder base
The healthcare company keeps Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and will be led by David Joyner, the current chairman and chief executive. The other, to be called CVS Pharmacy, takes the retail stores, mail pharmacy, MinuteClinic and virtual care, led by Prem Shah, now group president. Shareholders will own stock in both companies, and each is expected to carry a solid investment grade rating, with completion still subject to final board approval, an effective Form 10 registration statement with the SEC and confirmation of the tax-free treatment. As of Sept. 30, the company counted about 9,000 retail pharmacies, more than 1,000 clinics, a PBM serving roughly 87 million plan members and an estimated 37 million people through its insurance products.
The integration thesis, reversed
The pharmacy company will keep nearly 30,000 pharmacists and, in the company's words, pursue a wider set of partnerships across the healthcare system, including with payers, pharmacy benefit managers and manufacturers. That is the quiet reversal. The chain CVS once bought Aetna to bind to its insurance and PBM operations will be free to sign deals with any of them, including rival PBMs, because it will no longer share an owner with Caremark. The businesses that stay combined are the ones that carry the political exposure.
CVS had reached this decision once before and walked away. In 2024 it considered a breakup and dropped the idea, with Joyner saying the company was in a turnaround and lacked the flexibility, cash and business performance to execute a split. That turnaround meant $2 billion in cost cuts, store closures and leadership shakeups. Jefferies analyst Brian Tanquilut summed up the change: "Back then, the idea of retail standing alone was unthinkable."
Why the timing finally works
The financial foundation has changed. Joyner told CNBC the company has now posted eight consecutive quarters of beating Wall Street earnings estimates. The retail pharmacy segment still runs on thin economics, with adjusted operating margins of roughly 4% to 5%, but analysts describe it as stable and profitable enough to stand on its own, helped by retrenchment at Walgreens and Rite Aid, whose store closures thinned the field, and by CVS's CostVantage model, which ties reimbursement to the company's own costs.
The pressure on Caremark
The PBM staying behind is also the one in the crosshairs. Tennessee and Arkansas have passed laws that would bar one company from owning both a pharmacy and a PBM, though the Arkansas measure is held up in court, and Leerink analyst Michael Cherny has pointed to a mounting litany of state lawsuits. Joyner has said the company is not splitting up because of regulatory issues. The timing will test that claim: the announcement came the day after Democrats won control of Congress, with drug pricing and PBM reform expected back on the legislative agenda. Caremark is one of the country's three largest PBMs.
Can contracts do what ownership did?
Joyner told analysts the synergy between the businesses would be "preserved in commercial agreements between the two organizations" and that "we don't need the integration of an operating structure," with the company spending the next 15 to 18 months working on those agreements. Cherny's open question is whether future contractual arrangements can preserve the same competitive advantages and flexibility that common ownership provides today. RBC analyst Ben Hendrix added another: the discount investors already assign to the retail pharmacy unit has weighed on CVS's overall value, and the split raises questions about how separation would affect Aetna's Medicare Advantage quality ratings.
However the commercial agreements turn out, the structure itself tells the story. The drugstore walks away as a neutral front door, free to partner with payers, manufacturers and pharmacy benefit managers that are not its own. Aetna and Caremark keep the integration, and the regulatory and political risk, under one roof. Investors sold the news anyway.
